Impurity/Aggregation Analysis

Given the complex structures of biopharmaceuticals, there is a possibility for the induction of enzymatic and non-enzymatic modifications during production, storage, and transportation. Protein samples may aggregate during production and storage, which is inappropriate because it could result in immunogenicity…